Pharma Focus Asia

SK bioscience Receives Emergency Use Listing for SKYCovione

Wednesday, June 21, 2023

SK Bioscience has announced that its COVID-19 vaccine, SKYCovione, has been granted Emergency Use Listing by the World Health Organisation.

SKYCovione is a self-assembled nanoparticle vaccine that specifically targets the receptor binding domain of the SARS-CoV-2 Spike protein, which is responsible for the virus's entry into human cells. Based on the immunogenicity and safety profile, SKYCovione becomes the 12th COVID-19 vaccine to be granted Emergency Use Listing.

SKYCovione is the world’s first medicine developed using computational protein design, an approach that uses Rosetta software to engineer protein structures with enough precision to place individual atoms exactly where desired.

In Phase III clinical trials, SKYCovione demonstrated the ability to induce neutralising antibody responses against the parent strain of SARS-CoV-2.

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference